Clinical Trials: What You Need to Know

+ -Text Size


Submission for FDA approval: New drug application (NDA)

In the United States, when phase III clinical trials show a new drug is more effective and/or safer than the current standard treatment, a new drug application (NDA) is submitted to the Food and Drug Administration (FDA) for approval. The FDA then reviews the results from the clinical trials and other relevant information. The FDA may ask for more information or even require that more studies be done. This can extend the approval process to more than 5 years.

Based on its review, the FDA decides if the treatment is OK to be used in patients with the type of illness the drug was tested on. If it is, the new treatment often becomes the standard of care, and newer drugs must then be tested against it before being approved. But, in some cases, the clinical trials are still not over and phase IV trials continue.

Last Medical Review: 09/25/2014
Last Revised: 10/31/2014